How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France - Archive ouverte HAL Access content directly
Journal Articles Revue Economique Year : 2017

How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France

, (1) , (2) , (3) , (4) , (5, 6)
1
2
3
4
5
6

Abstract

BRCA1/2 carriers have a higher risk of developing breast and ovarian cancer at a younger age. Preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) are two of the few options available to avoid transmitting the mutation. To inform the bioethics debate about authorization, a contingent valuation survey elicited preferences regarding access to PGD and PND from a sample of 460 unaffected by cancer BRCA1/2 carriers (GENEPSO cohort). We find that the respondents can be classified into three groups: one opposed to PGD/PND (28.3%), one strongly in favour of PGD/PND (45.8%), and one in an intermediate position (25.9%). We look for the determinants of these preferences, especially of the willingness to pay for PGD/PND. Overall, we find that BRCA1/2 carriers support access to PGD/PND, which has implications for recommendations to decision-makers.

Dates and versions

hal-01589998 , version 1 (19-09-2017)

Identifiers

Cite

Christel Protière, Olivier Chanel, Emmanuelle Mouret-Fourme, Claire Julian-Reynier, Catherine Noguès, et al.. How Can Contingent Valuation Inform the Bioethics Debate? Evidence from a Survey on Hereditary Cancers in France. Revue Economique, 2017, 68 (3), pp.379--404. ⟨10.3917/reco.683.0379⟩. ⟨hal-01589998⟩
195 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More